Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

Share Price is delayed by 15 minutes
Get Live Data
2,206.00    32.00 (1.47%)
Bid:
2,186.00
Ask:
2,200.00
Spread: 14.00 (0.64%)
Market Cap: £1.47b
GNS Live PriceLast checked at - London Stock Exchange

Intraday Genus Share Chart

Pre-Close Trading Update

9 Jul 2009 07:00

RNS Number : 3707V
Genus PLC
09 July 2009
 



For immediate release 9 July 2009

GENUS plc

("Genus" or "the Company")

Pre-Close Trading Update

Genus, a world leading animal genetics company, today provides the following update on trading for the six months to 30th June 2009.

Despite tough short-term market conditions driven by the general economic slowdown, Genus continues to expect to report a strong increase in profits for the year to 30 June 2009, with the results benefiting from the international diversity of the Group's operations and the weakness of sterling.

Whilst market conditions for Genus' customers have remained challenging, trading for Genus has been broadly in-line with the Board's expectations during the final quarter. The one exception was a further weakness in the North American dairy market caused by exceptionally low milk prices. Nevertheless, Genus continues to expect that adjusted profit before tax* for the full year will be in line with market expectations. 

For further information contact:-

Genus plc Tel: 01256 345970

Richard Wood, Chief Executive

John Worby, Finance Director

Buchanan Communications Tel: 0207 466 5000

Charles Ryland/Isabel Podda/Jennie Spivey

This announcement is available on the Genus website, www.genusplc.com

*Adjusted Profit Before Tax represents profits before tax excluding non cash items relating to the fair value movement on biological assets, amortisation of acquired intangibles, share based payments and exceptional items. This measure is used to demonstrate underlying performance and in the current year is being amended to exclude only that part of amortisation relating to acquired intangibles. This amendment in accounting treatment amounts to a net reduction in adjusted profit before tax of £0.6m (2008:£0.1m). 

About Genus

Genus creates advances to animal breeding through biotechnology and sells added value products for livestock farming and food producers. Its non-Genetically Modified Organism (GMO) technology is applicable across all livestock species but is only commercialised by Genus in the bovine and porcine farming sectors.

Genus' worldwide sales are made in seventy countries under the trademarks "ABS" (dairy and beef cattle) and "PIC" (pigs) and comprise semen and breeding animals with superior genetics to those animals currently in production. Customers' animals produce offspring with greater production efficiency, milk and meat output and quality and use these to supply the global dairy and meat supply chain. 

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and the Group's global production and distribution network.

Headquartered in BasingstokeEngland, Genus companies operate in 30 countries on six continents, with research laboratories located in MadisonUSA.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTEAKXPESSNEFE
Date   Source Headline
24th May 20234:54 pmRNSNotification of Major Holdings
18th May 20231:32 pmRNSDirector/PDMR Shareholding
16th May 20236:16 pmRNSDirector/PDMR Shareholding
16th May 20237:00 amRNSTrading Update
9th May 20234:30 pmRNSNotification of Major Holdings
3rd May 20238:44 amRNSTotal Voting Rights
2nd May 20237:00 amRNSShare Award for Incoming CEO
3rd Apr 202311:27 amRNSTotal Voting Rights
3rd Apr 20237:00 amRNSAppointment of Chief Executive Officer Designate
21st Mar 20232:58 pmRNSApplication for Block Listing
6th Mar 202312:53 pmRNSNotification of Major Holdings
2nd Mar 20231:51 pmRNSNotification of Major Holdings
1st Mar 20232:20 pmRNSNotification of Major Holdings
24th Feb 20235:13 pmRNSDirector/PDMR Shareholding
24th Feb 202311:39 amRNSNotification of Major Holdings
23rd Feb 20239:33 amRNSReplacement: Interim Results
23rd Feb 20237:00 amRNSChief Executive Officer Retirement
23rd Feb 20237:00 amRNSInterim Results
21st Feb 20235:03 pmRNSNotification of Major Holdings
10th Feb 20232:08 pmRNSNotification of Major Holdings
1st Feb 202310:00 amRNSBlock listing Interim Review
23rd Nov 20221:02 pmRNSResult of AGM
23rd Nov 20227:00 amRNSAGM Trading Update
3rd Nov 20227:00 amRNSRuthin Site Visit
14th Oct 202211:39 amRNSTR-1: Notification of Major Holdings
14th Oct 20227:00 amRNSAnnual Report and Annual General Meeting
15th Sep 202210:55 amRNSNotification of Major Holdings
14th Sep 20224:41 pmRNSDirector/PDMR Shareholding
13th Sep 20226:08 pmRNSDirector/PDMR Shareholding
8th Sep 20221:57 pmRNSNotification of Major Holdings
8th Sep 20227:00 amRNSPreliminary Results
2nd Sep 20229:05 amRNSTotal Voting Rights
2nd Aug 20227:00 amRNSAppointment of Joint Corporate Broker
1st Aug 202210:10 amRNSBlock listing Interim Review
21st Jul 202210:21 amBUSForm 8.3 - Genus Plc - CORRECTION
21st Jul 202210:05 amRNSHolding(s) in Company
20th Jul 20223:03 pmRNSNotification of Major Holdings
19th Jul 202211:57 amBUSForm 8.3 - Genus Plc
5th Jul 20222:10 pmRNSNotification of Major Holdings
1st Jul 20229:35 amRNSTotal Voting Rights
24th Jun 20223:42 pmRNSNotification of Major Holdings
6th Jun 20229:11 amRNSNotification of Major Holdings
1st Jun 202212:45 pmRNSNotification of Major Holdings
30th May 202212:18 pmRNSNotification of Major Holdings
17th May 20229:26 amRNSNotification of Major Holdings
21st Apr 20227:00 amRNSNotification of Major Holdings
19th Apr 20221:50 pmRNSNotification of Major Holdings
31st Mar 20221:34 pmRNSDirector Declaration
28th Mar 20225:36 pmRNSNotification of Major Holdings
8th Mar 20223:47 pmRNSNotification of Major Holdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.